Global Retirement Partners LLC Takes $975,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Global Retirement Partners LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 1,564 shares of the biopharmaceutical company’s stock, valued at approximately $975,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $226,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $3,183,000. Gabelli Funds LLC lifted its stake in Regeneron Pharmaceuticals by 3.0% in the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after buying an additional 55 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after buying an additional 5,120 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $810.24 on Wednesday. The stock has a market capitalization of $83.42 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.37 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $683.57 and a two-hundred day moving average price of $714.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the firm earned $12.81 EPS. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $482,400. The trade was a 39.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on REGN shares. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Leerink Partners boosted their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research report on Tuesday, July 7th. Finally, Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Sixteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $801.70.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Leerink raises price target: Leerink Partners increased its REGN price target from $641 to $824, implying modest additional upside. However, the firm retained a “market perform” rating, suggesting limited conviction in a stronger near-term advance. Benzinga analyst price target report
• Neutral Sentiment: Class-action deadline approaches: Several law firms, including Pomerantz, Hagens Berman, Faruqi & Faruqi, and The Schall Law Firm, reminded investors of a September 14, 2026 deadline to seek lead-plaintiff status in a securities lawsuit. These announcements largely repeat previously reported information and do not represent a new financial or regulatory finding. Pomerantz investor alert
• Negative Sentiment: Litigation highlights clinical-trial concerns: The lawsuits allege that Regeneron made misleading statements about clinical differentiation and slowing event accrual in the Phase 3 fianlimab-Libtayo study, potentially understating the risk that the trial would miss its primary endpoint. The trial failure reportedly erased roughly $11 billion in market value and could create ongoing legal costs, reputational risk, and uncertainty around the program’s commercial prospects. The allegations have not been proven. Hagens Berman Regeneron class-action notice

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.